Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Encoding preferences in memory were examined in 22 subjects with presumed dementia of the Alzheimer type (DAT), 22 subjects with presumed multi-infarct dementia (MID), and 19 elderly depressed subjects by means of multiple-choice recognition testing of memory for word lists where target words appeared in choice arrays amongst semantic, acoustic and unrelated distractor words. Performance was worse in dementia than in depression. Subjects with dementia tended to make many unrelated error choices, and in DAT this tendency was stronger in more impaired subjects; but there were no significant differences between groups in the proportions of different types of errors made.
 ...
PMID:Encoding preferences in memory in dementia. 236 5

Hallucinations may occur in any sensory modality. Auditory hallucinations, usually ascribed to psychiatric illness, take various forms including the perception of voices, cries, noises, or rarely, music. Formed musical hallucinations, (ie, the perception of either vocal or instrumental melodies), reported in the English literature to date have typically been associated with marked hearing loss, advanced age (average 67.8 years), female sex (71%), lack of response to treatment, and general lack of associated psychopathology. We have collected data on seven additional patients with musical hallucinations. The average age of these patients was 72.9 years; all were women. Six had significant hearing problems. All reported onset of musical hallucinations after the age of 60. Interestingly, all seven had major psychiatric illnesses. Four had major depression, two had late-onset schizophrenia, and one had multi-infarct dementia. Of the five who had CT scans, one was normal and the rest demonstrated varying degrees of brain pathology. Neuroleptics were used with varying results in three cases; antidepressants were used in two depressed patients and were temporally related to the onset of musical hallucinations in one patient. Electroconvulsive therapy (ECT) was very effective in treating depression and musical hallucinations in the three patients for whom it was used, usually providing relief from hallucinations after only two treatments. Our collection of cases demonstrates that musical hallucinations can occur in association with psychiatric illness, and perhaps unlike the hallucinations associated with isolated hearing loss, may respond to conventional treatments for the underlying psychiatric disorder. Hearing loss is neither a necessary nor sufficient condition for the occurrence of musical hallucinations.
 ...
PMID:Musical hallucinations. The sounds of silence? 256 62

Positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) was employed to assess regional cerebral glucose metabolism which is tightly coupled to neuronal activity in the brain. In Alzheimer's and multi-infarct dementia, hypometabolism of glucose was found in frontal, temporal, and parietal association cortices. Focal hypometabolism in association cortices was observed in depression, epilepsy, ALS and other neurological diseases without any symptoms of mental deterioration. These results might indicate that not focal but global decrease of neuronal activity in the association cortex induces demented state.
 ...
PMID:[Cerebral glucose metabolism in dementia (PET-FDG study)]. 260 Oct 96

A double-blind, placebo-controlled trial was carried out in 40 patients affected by multi-infarct dementia to see if a daily intravenous infusion of 3 mg co-dergocrine mesylate ('Hydergine') over 14 days would improve severely deteriorated elderly patients and shorten the latent period (3 months) which is observed when the drug is given orally. All the patients had severe mental impairment, psychological deficit or altered consciousness. A Hachinski score of 7 or more, and a cumulative score of at least 12 points on SCAG scale Items 1, 2 and 4 (anxiety/depression) and/or Items 5, 6 and 8 (alertness/confusion) were required for admission. After 1 week of intravenous infusion of placebo, patients were randomly allocated to treatment with co-dergocrine mesylate or placebo, from Day 1 to Day 14. The solutions were infused over a period of 2 hours. During the follow-up period from Day 15 to Day 21, the patients did not receive any treatment. Thirty-six patients (17 on co-dergocrine mesylate, 19 on placebo) completed the study. The results, as rated on the SCAG scale, indicated significant improvements, in favour of co-dergocrine mesylate, in cognitive dysfunction, mood depression, withdrawal and overall impression. Furthermore, the factor fatigue on the Nowlis scale and clinical global assessments by physicians also showed significant advantages of the co-dergocrine mesylate group over placebo. Nine out of 17 co-dergocrine mesylate patients complained of side-effects, usually experienced during infusion; they consisted mainly of nausea (6 patients), gastric discomfort (2 patients), and tremor, nasal congestion, flushing, hypotension and hypertension (1 patient each). Despite the appearance of side-effects, general tolerability was rated as 'good' by both physicians and patients. It is concluded, therefore, that intravenous high dose co-dergocrine mesylate treatment has a fast and clinically relevant effect on the key clinical symptoms of multi-infarct dementia.
 ...
PMID:Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial. 268 Feb 86

The different methods of measuring the intracranial CSF spaces on CT images are described. The values obtained are demonstrated to separate the normal aging brain from the brain in senile dementia of Alzheimer's type. The CT criteria for the diagnosis of multi-infarct dementia are shown. The significance of CT studies in senile depression is discussed. The problem of vascular encephalopathy (leuko-araiosis) in normal aging of the brain and in dementia is considered in particular, and even the occurrence of intracranial space-occupying lesions and normal pressure hydrocephalus, as treatable causes of dementia and depression, are mentioned. The data and results of my own CT research on normal brain aging, dementia and depression are presented with reference to the literature.
 ...
PMID:[Problems in CT diagnosis of the aging brain]. 269 69

EVINCE-I is an expert system for neuropsychiatric diagnostics implemented on a personal computer. It is developed to assess the possibilities of an expert system which models the procedures used for medical decision taking and data analysis by a neuro-psychiatrist when making a differential diagnosis in the domain of dementia syndromes. The knowledge of the system centers around detection of Alzheimer's disease, multi-infarct dementia and depression-induced dementia. EVINCE-I and the human expert were compared in their ability to diagnose 29 patients, i.e. 19 patients with early stages of dementia and 10 patients showing varying disorders except dementia. It is shown that EVINCE-I is able to detect dementia and its main causes, and produce diagnoses that agree with those of the human expert.
 ...
PMID:[An experimental expert system for the differential diagnosis of the dementia syndrome. Initial evaluation]. 272 97

The Fuld Object Memory Evaluation (Fuld, 1981) was administered to 80 elderly adults (aged 60 to 90 years) who were hospitalized for evaluation and treatment of primary degenerative dementia (PDD), other organic disorders (e.g., Parkinson's disease or multi-infarct dementia), or major depression. Although mean performance in each of the diagnostic groups was below normative levels reported by Fuld (1981), PDD patients performed significantly more poorly than those with depression or other organic disorders. Analysis of subscore patterns failed to support the hypothesis of a selective memory deficit in depression, and substantial overlap in scores was observed between the depressed group and patients with organic disorders other than PDD. Object Memory Evaluation performance was influenced by global mental status and secondary psychiatric diagnoses, but not by education, age, or physical health.
 ...
PMID:Patterns of performance on the Fuld Object Memory Evaluation in elderly inpatients with depression or dementia. 276 Jan 77

Monoamine oxidase-B (MAO-B) activity of platelets of an age- and sex-matched group of controls was compared with several groups of inpatients having non-familial dementia of Alzheimer type (DAT), Parkinson's disease (PD), multi-infarct dementia (MID), mixed types of these 3 diseases and a group of other central nervous system (CNS) organic disorders. All patients were subjected to several psychometric tests, including the Sandoz Clinical Assessment--Geriatric Scale, Hamilton Rating Scale for Depression, Mini-Mental State Examination and the Organic mental Disorder Scale (OMDS). A statistically significant enhancement of MAO-B activity could be observed in DAT patients and in PD patients, whereas the MID group showed a mean activity similar to that of the control group and the group with other organic CNS disorders. In DAT patients the degree of dementia in the OMDS test and the enhancement of MAO activity were positively correlated, but PD did not show such a correlation. It is concluded that the increase of MAO activity in PD and in DAT might be due to a disease-related enhanced affinity to oxygen and to such oxygen-derived radicals as superoxide or hydroxyl radicals. However, a possible drug-induced enhancement of MAO activity in PD cannot be excluded. Furthermore, the MAO-B activity values in platelets of individual patients or controls are not indicative of diagnosis or prognosis of any of these diseases and are of no disease-related specificity.
 ...
PMID:Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia. 322 31

The effect of piracetam (a putative enhancer of cerebral metabolism) on regional CMRGlu was studied by positron emission tomography of 2[18F]-fluoro-2-deoxy-D-glucose in nine patients with Alzheimer's disease, and in seven cases with multiinfarct dementia or unclassified dementia. In Alzheimer's disease, i.v. administration of piracetam, 6 g b.i.d. for 2 weeks, significantly improved rCMRGlu in most cortical areas, whereas no effect on CMRGlu of the drug was observed in the multiinfarct dementia/unclassified dementia groups. These results lend further support to the notion that adjuvant piracetam treatment is of benefit in Alzheimer's disease. They may also indicate that the typical metabolic depression in Alzheimer's disease is caused by complex interaction of disturbed transmitter and cellular function rather than by a specific deficit in the cholinergic system alone.
 ...
PMID:Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. 326 May 97

75 patients, aged 69 to 97 (mean 84) years, admitted to a geriatric clinic with symptoms or signs of organic brain failure, were examined with a wide test battery including chemical analyses, electroencephalogram (EEG), regional cerebral blood flow (rCBF) measurement, and psychometric tests. There was a prevalence of 89% organic dementia, 3% treatable dementia, and 8% non-dementia conditions. Thus the prevalence of treatable conditions was rather low (11%). Multi-infarct dementia was more prevalent (52%) than dementia of Alzheimer type (31%). All but one of the non-dementia conditions were due to confusional reaction. In no case was depression, drug intoxication, or deafness the only cause of symptoms. After a follow-up period of 6 months, 33% of the patients had died. An autopsy was performed in 80% of these cases, and the clinical diagnosis was confirmed in all but four cases.
 ...
PMID:Screening of patients admitted to a geriatric hospital with supposed organic dementia. 345 85


<< Previous 1 2 3 4 5 6 Next >>